PHASE I STUDY OF RO6958688 +/- OTHER ANTI-CANCER AGENTS IN PATIENTS WITH ADVANCED SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Cibisatamab (Primary) ; Atezolizumab
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 13 Sep 2018 Status changed from recruiting to discontinued.
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.
- 16 Nov 2017 New trial record